CombinatoRx, Incorporated (NASDAQ: CRXX) today reported financial results for the second quarter ended June 30, 2010. “With Exalgo approved and launched in the U.S. market...
CombinatoRx, Incorporated (NASDAQ: CRXX) announced today that it is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set...
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea’s...
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it currently plans to hold its 2010 Annual Meeting of Stockholders on September 8, 2010 at 8:30 a.m. Eastern Time...
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that Mark Corrigan, President and CEO is scheduled to present at the Noble Financial Sixth Annual Equity Conference at...
CombinatoRx, Incorporated (NASDAQ: CRXX) today reported financial results for the first quarter ended March 31, 2010. “In the last month our commercial partner Covidien...
DALLAS, May 5, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring CombinatoRx Inc. (Nasdaq:CRXX). The report includes financial, comparative and investment...
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be...
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the publication of new preclinical data in BLOOD, The Journal of the American Society of Hematology. In the article...
CALGARY, Alberta, March 26, 2010 (GLOBE NEWSWIRE) -- Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約